Aurobindo Pharma Ltd., a major Indian pharmaceutical company, has announced a share buyback plan totaling ₹800 crore to repurchase 54,23,728 fully paid-up equity shares at a price of ₹1,475 each. This buyback, which represents 0.93% of the company's total outstanding equity shares, is set to benefit investors holding shares in their demat accounts as of the close on April 16. The buyback will be conducted through a tender offer, allowing eligible shareholders to sell their shares at a predetermined price, typically higher than the current market value. Following this announcement, Aurobindo Pharma's shares increased nearly 2%, reaching a day's high of ₹1,358 on the National Stock Exchange (NSE). Over the past month, the stock has appreciated approximately 8%, contrasting with a decline of over 11% in the Nifty 50 index during March. Aurobindo Pharma's stock has shown a robust performance, gaining about 21% over the last six months and nearly 11% year-to-date. This marks the company's first buyback since August 2024, when it repurchased shares at ₹1,460 each.